Innovation
Most supplement categories have settled on a similar ingredient set at a similar dose, because the evidence points in the same direction for everyone. Differentiation on composition alone has become difficult, and price competition follows.
Delivery offers a genuine alternative. If the same ingredient can be absorbed more completely, act more quickly, or be taken more conveniently, that is a real advantage rather than a repositioning. It is also defensible, because the technology can be protected in ways a formula rarely can.
The difficulty is that delivery claims are harder to substantiate than ingredient claims, and the category contains a great deal of assertion that has never been measured.
Liposomal encapsulation surrounds an active in a phospholipid bilayer, intended to improve absorption and protect the ingredient through the digestive tract. The evidence varies considerably by active and by the quality of the liposome, and the term is used loosely across the market.
Nanoemulsion reduces droplet size to increase surface area and improve dispersion of lipophilic actives in aqueous systems. Useful for beverages and for fat-soluble ingredients that otherwise absorb poorly.
Buccal and sublingual delivery bypasses first-pass metabolism by absorbing through the oral mucosa. Genuinely advantageous for actives substantially degraded in the liver, and of limited benefit for those that are not.
Sustained and delayed release controls where and when an active is liberated, whether to extend duration, protect an acid-sensitive ingredient, or target release further down the tract.
Complexation and co-crystal approaches alter the physical form of an active to improve solubility, which for poorly soluble compounds is often the limiting factor in absorption.
This is where the category is weakest. A claim that a delivery system improves absorption is a pharmacokinetic claim, and substantiating it requires pharmacokinetic evidence.
That means a human crossover study measuring plasma levels over time against a comparator, producing area under the curve, peak concentration and time to peak. In vitro dissolution data is supporting evidence, not substitution. A supplier’s claim about their ingredient is their claim, and it does not automatically transfer to your finished product.
The important distinction is between the technology and your product. A liposomal technology with good published data does not substantiate your formula unless your formula was what was studied, or is close enough to justify a read-across you can defend.
Novel delivery affects regulatory position in ways that catch brands out.
In Canada, a delivery format outside monograph parameters can push a product from Class II to Class III, changing the review target from 90 days to 210 and requiring a full safety and efficacy dossier.
In the European Union, a novel delivery system may raise novel food questions if the resulting substance was not consumed to a significant degree before May 1997, even where the underlying active is entirely familiar.
In Australia, permitted ingredient determinations specify forms and preparations, and a novel form may not be covered.
Across markets, a delivery system that meaningfully increases absorption raises a safety question that did not previously exist. If the same label dose now delivers substantially more active, the safety assessment was done at the old exposure.
Novel delivery narrows your manufacturing options sharply. Few contract manufacturers can produce a genuine liposomal or nanoemulsion product, and fewer can do it at commercial scale with consistent particle size.
That has consequences beyond finding a site. It affects your negotiating position, your second sourcing options, your minimum volumes and your risk if the relationship fails. Analytical control is harder too, since particle size distribution, encapsulation efficiency and stability of the delivery system all need specifying, testing and monitoring alongside the active itself.
Stability is the frequent failure point. A delivery system that performs at manufacture and degrades over shelf life delivers an ordinary product with an extraordinary claim on the label.
Novel delivery is worth the cost and complexity when the active genuinely has an absorption problem, when the improvement is large enough to matter clinically rather than statistically, when you can afford to substantiate it properly, and when your manufacturing and analytical capability can hold it through shelf life.
It is not worth it when the active already absorbs well, when the benefit exists only in vitro, or when the objective is a marketing term rather than a measurable difference. The category has enough of the latter that buyers and regulators have both become sceptical, which raises the evidentiary bar for everyone doing it properly.